<a href="https://www.medchemexpress.com/ARV-771.html">ARV-771</a>产品描述:ARV-771 is a potent bromodomain and extra-terminal (<b>BET</b>) proteins degrader with <b>K<sub>d</sub></b> values of 4.7, 7.6, 7.6 nM against bromodomain 2, 3 and 4, respectively. IC50 & Target: Kd: 4.7 (BRD 2), 7.6 (BRD 3), 7.6 nM (BRD 4)<sup>[1]</sup> IC50: less than 1 nM (c-MYC protein)<sup>[1]</sup> <i><b>In Vitro:</b></i> ARV-771 potently degrades BRD2/3/4 in 22Rv1 cells with a DC<sub>50</sub> less than 5 nM. c-MYC protein is a downstream effector of BET proteins. Treatment with ARV-771 results in depletion of c-MYC with an IC<sub>50</sub> of less than 1 nM. ARV-771 shows strong antiproliferative effect on 22Rv1, VCaP, and LnCaP95 cell lines. ARV-771 treatment has a pronounced effect on cell morphology consistent with apoptosis. FL-AR and AR-V7 mRNA are down-regulated upon treatment with 10 nM ARV-771 in VCaP cells. ARV-771 has an antiandrogenic effect on a number of AR-regulated genes in VCaP cells<sup>[1]</sup>. <i><b>In Vivo:</b></i> Treatment of non castrated male Nu/N<br><br> <br> <span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">公司介绍:MedChemExpress(MCE)专注于各种抑制剂、激动剂、API及化合物库,总部位于美国新泽西,分别在瑞典和上海设有欧洲区子公司和亚洲区总代理,营销网点遍及全球20多个国家地区。MCE经过多年努力已成为全球生物活性小分子领域的一流供应商, 产品涵盖癌症、神经科学、抗感染、表观遗传学等20个热门研究领域,PI3K、MAPK等近千个细分靶点,超过4000个活性小分子化合物现货,以及GPCR、API、离子通道等超过20种不同类型的化合物库,同时提供从毫克到千克的专业定制合成服务。</span> <br style="color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;line-height: 22.0px;background-color: rgb(251,251,251);"> <span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">MCE 对每批产品都进行严格的LCMS和NMR检验,其产品已被全球近万名客户广泛使用并发表大量文章、专利;</span> <br style="color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;line-height: 22.0px;background-color: rgb(251,251,251);"> <span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">MCE 定期增加各领域热门抑制剂、激动剂,不断扩增已有化合物库,以满足最新的科研需求;</span> <br style="color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;line-height: 22.0px;background-color: rgb(251,251,251);"> <span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">数千种产品在上海有充足备货,24-48小时内送达客户;</span> <br style="color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;line-height: 22.0px;background-color: rgb(251,251,251);"> <span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);">大量产品提供免费试用装;</span> <span style="outline: 0.0px;line-height: 22.0px;color: rgb(62,62,62);font-family: "Helvetica Neue" , Helvetica , Arial , sans-serif;font-size: 11.818182px;background-color: rgb(251,251,251);"> 已为全球多个知名企业、院校构建各种定制型化合物库。</span><br><br>产品链接:<a href="http://www.medchemexpress.cn/arv-771.html">www.medchemexpress.cn/arv-771.html</a><br><br></span><img style="width: 600.0px;height: 310.0px;" src="http://img.dxycdn.com/trademd/upload/userfiles/image/2014/08/A1408605159png_small.jpg" alt=""> |
ARV-771研究进展
发布日期:2017-10-27 浏览次数:0
核心提示:a href=https://www.medchemexpress.com/ARV-771.htmlARV-771/a产品描述:ARV-771 is a potent bromodomain and extra-terminal
- 下一篇:暂无
- 上一篇:Olcegepant (hydrochloride)研究进展
行业动态
更多...
- ARV-771研究进展 10-27
- Olcegepant (hydrochlorid 10-27
- Beaucage reagent研究进展 10-27
- Olcegepant研究进展 10-27
- EC330研究进展 10-27
- CEP-40783研究进展 10-27
- Conduritol B epoxide研究 10-27
- CDD3506研究进展 10-27
- CDD3505研究进展 10-27
- ML364研究进展 10-27